Sradha Kotwal1,2, Sarah Coggan1, Stephen McDonald3, Girish Talaulikar4,5, Alan Cass6, Stephen Jan1, Kevan R Polkinghorne7,8, Nicholas A Gray9,10, Martin Gallagher1,5. 1. The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. 2. Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia. 3. ANZDATA Registry, Adelaide, South Australia. 4. Renal Services, ACT Health, Canberra, Australian Capital Territory, Australia. 5. Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia. 6. Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. 7. Department of Epidemiology and Preventive Medicine, Monash University, Prahran, Victoria, Australia. 8. Departments of Nephrology and Medicine, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. 9. Sunshine Coast University Hospital, Birtinya, Queensland, Australia. 10. University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
Abstract
Background: Patients with hemodialysis central venous catheters (HD CVCs) are susceptible to health care-associated infections, particularly hemodialysis catheter-related bloodstream infection (HD-CRBSI), which is associated with high mortality and health care costs. There have been few systematic attempts to reduce this burden and clinical practice remains highly variable. This manuscript will summarize the challenges in preventing HD-CRBSI and describe the methodology of the REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) trial. Methods: The REDUCCTION trial is a stepped-wedge cluster randomized trial of a suite of clinical interventions aimed at reducing HD-CRBSI across Australia. It clusters the intervention at the renal-service level with implementation randomly timed across three tranches. The primary outcome is the effect of this intervention upon the rate of HD-CRBSI. Patients who receive an HD CVC at a participating renal service are eligible for inclusion. A customized data collection tool allows near-to-real-time reporting of the number of active catheters, total exposure to catheters over time, and rates of HD-CRBSI in each service. The interventions are centered around the insertion, maintenance, and removal of HD CVC, informed by the most current evidence at the time of design (mid-2018). Results: A total of 37 renal services are participating in the trial. Data collection is ongoing with results expected in the last quarter of 2020. The baseline phase of the study has collected provisional data on 5385 catheters in 3615 participants, representing 603,506 days of HD CVC exposure. Conclusions: The REDUCCTION trial systematically measures the use of HD CVCs at a national level in Australia, accurately determines the rate of HD-CRBSI, and tests the effect of a multifaceted, evidence-based intervention upon the rate of HD-CRBSI. These results will have global relevance in nephrology and other specialties commonly using CVCs.
Background: Patients with hemodialysis central venous catheters (HD CVCs) are susceptible to health care-associated infections, particularly hemodialysis catheter-related bloodstream infection (HD-CRBSI), which is associated with high mortality and health care costs. There have been few systematic attempts to reduce this burden and clinical practice remains highly variable. This manuscript will summarize the challenges in preventing HD-CRBSI and describe the methodology of the REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) trial. Methods: The REDUCCTION trial is a stepped-wedge cluster randomized trial of a suite of clinical interventions aimed at reducing HD-CRBSI across Australia. It clusters the intervention at the renal-service level with implementation randomly timed across three tranches. The primary outcome is the effect of this intervention upon the rate of HD-CRBSI. Patients who receive an HD CVC at a participating renal service are eligible for inclusion. A customized data collection tool allows near-to-real-time reporting of the number of active catheters, total exposure to catheters over time, and rates of HD-CRBSI in each service. The interventions are centered around the insertion, maintenance, and removal of HD CVC, informed by the most current evidence at the time of design (mid-2018). Results: A total of 37 renal services are participating in the trial. Data collection is ongoing with results expected in the last quarter of 2020. The baseline phase of the study has collected provisional data on 5385 catheters in 3615 participants, representing 603,506 days of HD CVC exposure. Conclusions: The REDUCCTION trial systematically measures the use of HD CVCs at a national level in Australia, accurately determines the rate of HD-CRBSI, and tests the effect of a multifaceted, evidence-based intervention upon the rate of HD-CRBSI. These results will have global relevance in nephrology and other specialties commonly using CVCs.
Authors: Peter Pronovost; Dale Needham; Sean Berenholtz; David Sinopoli; Haitao Chu; Sara Cosgrove; Bryan Sexton; Robert Hyzy; Robert Welsh; Gary Roth; Joseph Bander; John Kepros; Christine Goeschel Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Eyal Zimlichman; Daniel Henderson; Orly Tamir; Calvin Franz; Peter Song; Cyrus K Yamin; Carol Keohane; Charles R Denham; David W Bates Journal: JAMA Intern Med Date: 2013 Dec 9-23 Impact factor: 21.873
Authors: Bruce M Robinson; Tadao Akizawa; Kitty J Jager; Peter G Kerr; Rajiv Saran; Ronald L Pisoni Journal: Lancet Date: 2016-05-22 Impact factor: 79.321
Authors: Steven M Brunelli; David B Van Wyck; Levi Njord; Robert J Ziebol; Laurie E Lynch; Douglas P Killion Journal: J Am Soc Nephrol Date: 2018-02-22 Impact factor: 10.121
Authors: Teryl K Nuckols; Emmett Keeler; Sally C Morton; Laura Anderson; Brian Doyle; Marika Booth; Roberta Shanman; Jonathan Grein; Paul Shekelle Journal: JAMA Intern Med Date: 2016-12-01 Impact factor: 21.873
Authors: Sradha Kotwal; Alan Cass; Sarah Coggan; Nicholas A Gray; Stephen Jan; Stephen McDonald; Kevan R Polkinghorne; Kris Rogers; Girish Talaulikar; Gian Luca Di Tanna; Martin Gallagher Journal: BMJ Date: 2022-04-12